Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2021
2021 World Conference on Lung Cancer
Conference Program for 2021 the World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
-
+
P15 - Immunotherapy (Phase II/III Trials) - Early Stage NSCLC
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 2
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P15.01 - Phase II Prospective Study of Adjuvant Pembrolizumab in N2 Positive NSCLC Treated With Neoadjuvant CCRT Followed by Surgery
00:00 - 00:00 | Presenter: Sehhoon Park
- Abstract
Loading... -
+
P15.02 - Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Yongchang Zhang
- Abstract
Loading...
-
+
P16 - Immunotherapy (Phase II/III Trials) - First-Line, Advanced NSCLC
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 7
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P16.01 - Clonal Landscape Predicts Outcome in Lung Squamous Cell Carcinoma Patients with a Low Tumor Mutational Burden
00:00 - 00:00 | Presenter: Stas Fridland
- Abstract
Loading... -
+
P16.02 - Atezolizumab, Bevacizumab and Chemotherapy (IMpower150) in Stage IV Non-Small Cell Lung Cancer: The Australian Experience
00:00 - 00:00 | Presenter: Samantha Larna Dean
- Abstract
Loading... -
+
P16.03 - SWItch Maintenance PEmbrolizumab in patients with Non Small Cell Lung Cancer (SWIPE): Final Analysis
00:00 - 00:00 | Presenter: Haris Charalambous
- Abstract
Loading... -
+
P16.04 - A Phase II Clinical Study Evaluating Camrelizumab Combined With Apatinib and Albumin Paclitaxel for Advanced Non-Small CellLung Cancer
00:00 - 00:00 | Presenter: Lin Wu
- Abstract
Loading... -
+
P16.05 - Real World Data of First-Line Treatment With Pembrolizumab for Highly PD-L1-Expressing NSCLC
00:00 - 00:00 | Presenter: maki kobayashi
- Abstract
Loading... -
+
P16.06 - Comparison of Clinical Outcomes of Patients With Advanced NSCLC In Clinical Trials and in the Real World Received PD-1/PD-L1 Inhibitor
00:00 - 00:00 | Presenter: Huijuan wang
- Abstract
Loading... -
+
P16.07 - ARC-10: Phase 3 Study of Zimberelimab ± Domvanalimab vs Standard Chemotherapy in Front-Line, PD-L1-High, Metastatic NSCLC
00:00 - 00:00 | Presenter: Yu-Chung Li
- Abstract
Loading...
-
+
P17 - Immunotherapy (Phase II/III Trials) - First-Line, Advanced, Squamous NSCLC
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 3
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P17.01 - KEYNOTE-407 China Extension Final Analysis: Pembrolizumab Plus Chemotherapy for the Treatment of Metastatic Squamous NSCLC
00:00 - 00:00 | Presenter: Ying Cheng
- Abstract
Loading... -
+
P17.02 - RATIONALE 307: A Subgroup Analysis of Tislelizumab Plus Chemo vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading... -
+
P17.03 - Sintilimab With Two Cycles Nab-Paclitaxel / Platinum as First Line Therapy for Advanced Squamous Non–Small-Cell Lung Cancer
00:00 - 00:00 | Presenter: Huijuan wang
- Abstract
Loading...
-
+
P18 - Immunotherapy (Phase II/III Trials) - IO and Targeted Therapy
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 1
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P18.01 - Treatment Efficacy of HER2-Mutant Lung Adenocarcinoma by Immune Checkpoint Inhibitors
00:00 - 00:00 | Author(s): Xiangling Chu
- Abstract
Loading...
-
+
P19 - Immunotherapy (Phase II/III Trials) - Previously Treated NSCLC
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
- Presentations: 2
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P19.01 - RATIONALE-303 Phase 3 Tislelizumab vs Docetaxel in Previously Treated Advanced NSCLC: China Subgroup Analysis
00:00 - 00:00 | Presenter: Yun Fan
- Abstract
Loading... -
+
P19.02 - Sintilimab Plus Docetaxel in Previously Treated Advanced NSCLC, Updates on Progression-Free and Overall Survival
00:00 - 00:00 | Presenter: Zhehai Wang
- Abstract
Loading...
-
+
P21 - Liquid Biopsy and Other Non-invasive Diagnostic Modalities - IO
- Type: Posters
- Track: Liquid Biopsy and Other Non-invasive Diagnostic Modalities
- Presentations: 2
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P21.01 - Selected ctDNA Panel Gene Sequencing for Neoantigen Discovery and Survival Prediction in Patients With Stage IV Non-Small Cell Lung Cancer
00:00 - 00:00 | Author(s): Yan Zhang
- Abstract
Loading... -
+
P21.02 - Real-World Concordance Between Tumor Mutational Burden From Blood and Tissue in Lung Cancer and Other Cancers
00:00 - 00:00 | Presenter: Jewel Park
- Abstract
Loading...
-
+
P22 - Liquid Biopsy and Other Non-invasive Diagnostic Modalities - Monitoring/Prognosis
- Type: Posters
- Track: Liquid Biopsy and Other Non-invasive Diagnostic Modalities
- Presentations: 6
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P22.01 - Personalized ctDNA Assay for MRD Detection and Treatment Response Monitoring in a Patient With Metastatic Lung Cancer
00:00 - 00:00 | Presenter: Georges Azzi
- Abstract
Loading... -
+
P22.02 - Combined Use of CYFRA 21-1, CA125 and CRP Predicts Survival of Metastatic NSCLC Patients With Stable Disease
00:00 - 00:00 | Author(s): Anika Mang
- Abstract
Loading... -
+
P22.03 - Role of Circulating Tumor Cell Subpopulations in Operable Non-Small Cell Lung Cancer Diagnosis and Prognosis
00:00 - 00:00 | Presenter: Emanuela Fina
- Abstract
Loading... -
+
P22.04 - Prospective Validation of an Eight Gene mRNA Signature in Plasma for the Diagnosis of Early Stage Lung Cancer
00:00 - 00:00 | Presenter: Ana María Giménez Capitán
- Abstract
Loading... -
+
P22.05 - Dynamic Monitoring of Blood Samples by PEAC Technology for Early-Stage Lung Cancer Patients After Surgery
00:00 - 00:00 | Author(s): Siyu Wang
- Abstract
Loading... -
+
P22.06 - Prognostic Value of Circulating Tumor Cells in Patients With Small Cell Lung Cancer Receiving Front-Line Treatment
00:00 - 00:00 | Presenter: Haohua Zhu
- Abstract
Loading...
-
+
P23 - Liquid Biopsy and Other Non-invasive Diagnostic Modalities - Screening and Early Detection
- Type: Posters
- Track: Liquid Biopsy and Other Non-invasive Diagnostic Modalities
- Presentations: 5
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P23.01 - Integration of Metabolomics and Transcriptomics to Reveal Metabolic Disorder in Early Lung Cancer for Non-invasive diagnosis
00:00 - 00:00 | Presenter: xinrong Jiang
- Abstract
Loading... -
+
P23.02 - Digital Multiplexed circRNA Analysis From Plasma-Derived Extracellular Vesicles of Lung Cancer Patients
00:00 - 00:00 | Presenter: Carlos Pedraz-Valdunciel
- Abstract
Loading... -
+
P23.03 - Novel Serum Extracellular Vesicles Based miR-153-3p Biomarker Combined to a Prediction Model for Determining Early-Stage Lung Cancer
00:00 - 00:00 | Presenter: Yuxia Deng
- Abstract
Loading... -
+
P23.04 - Serum Biomarkers Enhance Prognostic Value of Computed Tomography (CT) in Patients With Non-Small Cell Lung Cancer (NSCLC)
00:00 - 00:00 | Author(s): Thomas Muley
- Abstract
Loading... -
+
P23.05 - Chromosome 3p22.1 and 10q22.3 Amplification in Different Subtypes of Lung Adenocarcinoma
00:00 - 00:00 | Presenter: Qi Wang
- Abstract
Loading...
-
+
P24 - Liquid Biopsy and Other Non-invasive Diagnostic Modalities - Targeted Therapy
- Type: Posters
- Track: Liquid Biopsy and Other Non-invasive Diagnostic Modalities
- Presentations: 14
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P24.01 - Turnaround Time and Variant Prevalence of a Blood-based KRAS Test in Patients With NSCLC
00:00 - 00:00 | Presenter: Edgardo S Santos
- Abstract
Loading... -
+
P24.02 - Unique Efficacy of Ensartinib on Different ALK Fusion Subtypes Evaluated by Plasma ctDNA
00:00 - 00:00 | Author(s): Yunpeng Yang
- Abstract
Loading... -
+
P24.03 - Dynamic Circulating Tumor DNA Interim Results From The ALKternate Clinical Trial
00:00 - 00:00 | Presenter: Malinda Itchins
- Abstract
Loading... -
+
P24.04 - Concordance of Tissue and Cell-Free DNA-Based Next-Generation Sequencing in Patients With Lung Adenocarcinoma
00:00 - 00:00 | Presenter: Misha Tran
- Abstract
Loading... -
+
P24.05 - Using Liquid Biopsies to Guide First-Line Therapy Decisions in Patients With Metastatic Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Luis E. Raez
- Abstract
Loading... -
+
P24.06 - Resistance Mechanisms Exploring of NSCLC With Central Nervous System Metastases Using Liquid Biopsy of Cerebrospinal Fluid: A Real-World Study
00:00 - 00:00 | Presenter: Guilan Dong
- Abstract
Loading... -
+
P24.07 - An Ultra-Sensitive Protocol for ctDNA Mutation Detection With Application in Lung Cancers
00:00 - 00:00 | Presenter: Yue Pu
- Abstract
Loading... -
+
P24.08 - Lung Cancer Diagnosis in Absence of Adequate Tissue Molecular Analysis in Metastatic Disease by NGS Analysis of Plasma cfDNA
00:00 - 00:00 | Presenter: Christi M.J. Steendam
- Abstract
Loading... -
+
P24.09 - Association Between Circulating EGFR Mutant Tumor DNA and Tumor Lesion Glycolysis in Patients with EGFR Mutated Metastatic Lung Adenocarcinoma
00:00 - 00:00 | Presenter: Zhasmina Mihaylova
- Abstract
Loading... -
+
P24.10 - Identification of ctDNA using MassARRAY Technology in a Cross-Sectional Study of NSCLC Patients
00:00 - 00:00 | Author(s): Arutha Kulasinghe
- Abstract
Loading... -
+
P24.11 - Cell-Free Tumor DNA (ctDNA) Utility in Detection and Monitoring EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
00:00 - 00:00 | Presenter: Jason Agulnik
- Abstract
Loading... -
+
P24.12 - Biomarker Testing for Advanced Lung Cancer by Next-Generation Sequencing in Elderly Patients.
00:00 - 00:00 | Author(s): Jose Nicolas Minatta
- Abstract
Loading... -
+
P24.13 - Circulating Tumor Cells Predict Prognosis Following First-Generation EGFR-TKI Treatment in EGFR- and TP53-Mutant Non-Small Cell Lung Cancer
00:00 - 00:00 | Author(s): jing he
- Abstract
Loading... -
+
P24.14 - Validation of Companion Diagnostics for the Identification of Patients with EGFR Exon20ins NSCLC for Amivantamab Therapy
00:00 - 00:00 | Presenter: Timothy Jatkoe
- Abstract
Loading...
-
+
P25 - Locally Advanced Non-Small Cell Lung Cancer - Concurrent Chemotherapy/ Radiotherapy
- Type: Posters
- Track: Locally Advanced Non-Small Cell Lung Cancer
- Presentations: 2
- Coordinates: 9/08/2021, 00:00 - 00:00, ePoster Hall
-
+
P25.01 - Efficacy of Weekly Paclitaxel-Bevacizumab Combination in Advanced NSCLC: AVATAX, A Retrospective Multicentric Study
00:00 - 00:00 | Presenter: Geoffroy Bilger
- Abstract
Loading... -
+
P25.02 - Concurrent Chemoradiotherapy With Cisplatin + S-1 for Locally Advanced Non-Small Cell Lung Cancer: IPD Meta-Analysis
00:00 - 00:00 | Presenter: Yuri Taniguchi
- Abstract
Loading...
first
prev
